조현병 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Schizophrenia Drugs Market size is expected to reach USD 14.87 Billion in 2034 from USD 9.69 Billion (2025) growing at a CAGR of 4.87% during 2026-2034.

The Global Schizophrenia Drugs Market is growing steadily due to increasing mental health awareness and rising prevalence of psychiatric disorders globally. Urban stress, substance abuse, and genetic predisposition are key contributing factors. Governments and healthcare organizations are emphasizing early diagnosis and treatment accessibility. The expansion of healthcare coverage and mental health funding programs is encouraging higher prescription rates. Pharmaceutical companies are focusing on developing long-acting injectable antipsychotics to improve patient adherence and therapeutic effectiveness.

Market growth is also driven by advancements in atypical antipsychotic medications with improved safety profiles. Novel drug formulations targeting reduced side effects such as weight gain and metabolic complications are gaining traction. Increasing investments in neuroscience research are accelerating pipeline developments. Digital health platforms and telepsychiatry services are expanding patient outreach. Additionally, collaborations between research institutions and pharmaceutical firms are strengthening innovation capabilities and clinical trial progress.

In the future, personalized medicine approaches and biomarker-based therapies are expected to transform treatment strategies. Emerging markets in Asia-Pacific and Latin America are anticipated to witness significant growth due to improving psychiatric care infrastructure. Ongoing regulatory approvals for innovative drug candidates will enhance competition. Long-term growth will be supported by continuous awareness campaigns and mental health de-stigmatization initiatives. Overall, innovation and accessibility will remain key determinants of market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutic Class

• Second Generation
• Third Generation
• Others

By Treatment

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

COMPANIES PROFILED

• H Lundbeck AS, Otsuka Pharmaceutical Co Ltd, Janssen Pharmaceuticals Inc, Eli Lilly and Company, AstraZeneca, ALLERGAN, Vanda Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Alkermes plc, BristolMyers Squibb Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY THERAPEUTIC CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutic Class
• 4.2. Second Generation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Third Generation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutic Class
  • 7.2.2 By Treatment
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutic Class
  • 7.3.2 By Treatment
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutic Class
  • 7.4.2 By Treatment
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutic Class
  • 7.5.2 By Treatment
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutic Class
  • 7.6.2 By Treatment
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SCHIZOPHRENIA DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 H. Lundbeck A/S
  • 9.2.2 Otsuka Pharmaceutical Co. Ltd
  • 9.2.3 Janssen Pharmaceuticals Inc
  • 9.2.4 Eli Lilly And Company
  • 9.2.5 AstraZeneca
  • 9.2.6 ALLERGAN
  • 9.2.7 Vanda Pharmaceuticals Inc
  • 9.2.8 Sumitomo Dainippon Pharma Co. Ltd
  • 9.2.9 Alkermes Plc
  • 9.2.10 Bristol-Myers Squibb Company